Week 340 Review - Most of last week's gains are gone

It looks like last week was a blip, as we're back to normal this week with nearly all last week's gains wiped out. It was a slightly positive week until Friday, when a 1p drop in OPTI:Optibiotix led to a nosedive. The deficit between cost and value widened by £1,451 to £57,302 and portfolio value dropped back bellow £100k to £99,157.

There were no big fallers this week, which usually signals a positive week.

FXPO:Ferrexpo climbed 6% as tensions in the Ukraine began to ease slightly, but these are still 38% down so have a lot of recovering to do before my annual review date on 28th May.

BLU:Blue Star Capital have been very volatile lately, but in a good way this week as they went up by 8%. They are still 44% down but if there is any half decent news about Satoshipay then they could recover very quickly.

Share of the Week by miles is JLP:Jubilee Metals which increased by a spectacular 60% of my original purchase price and is now 300% up. I'm expecting this momentum to continue as they are well below fair price for the income they are now generating.

At least the drop wasn't enough to take us below the injection line.

I'm really struggling to get above the trend line.

Here's the ISA and shares portfolio after week 28 of year 7.

			Weekly Change
Cash	£29.55		-£3.75
Portfolio cost	£72,195.21		+£0
Portfolio sell value (bid price-commission)	£46,087.77	(-36.2%)	-£479.21
Potential profits	£2,615.29		+£520
Yr 7 Dividends	£22.16		+£0
Yr 7 Profit from sales	£3,664.29		+£0
Yr 7 projected avg monthly profit	£567.04	(15.4%)	-£21.60
Total Dividends	£1,365.31		+£0
Total Profit from sales	£27,788.23		+£0
Average monthly cash profit	£367.69	(10.0%)	-£1.13
(Sold stocks profit + Dividends - Fees / Months)
Compound performance	65%		+0%

Not too big a drop here thanks to the increase in value of JLP:Jubilee Metals by £520. It's taking all my willpower not to cash in any more profits here, but I've already sold too many so really need to hold these long term. There's no reason why they can't get to 100p in the next 5 years given the speed of growth, at which point I'll only need to sell 1,000 for each £1,000 to spend on something else instead of needing to sell 6,000 now.

Annual performance is still great and long term performance has just about stayed on 10% for another week.

Such a long way to get back to the cost line.

Well below the trend line and dragging it steeper

The SIPP looks like this after week 324 overall and week 12 of year 7.

			Weekly Change
Cash	£67.14		-£504.33
Portfolio cost	£81,534.58		+£1,007.64
Portfolio sell value (bid price - commission)	£51,925.42	(-36.3%)	-£994.85
Potential profits	£118.19		-£6.06
Yr 7 Dividends	£81.54		+£0
Yr 7 Interest	£0		+£0
Yr 7 Profit from sales	£381.04		+£0
Yr 7 projected avg monthly profit	£148.86	(3.6%)	-£20.11
Total Dividends	£3,285.93		+£0
Total Interest	£0.20		+£0
Total Profit from sales	£24,105.67		+£0
Average monthly cash profit	£354.68	(8.5%)	-£1.32
(Sold stocks profit + Dividends - Fees / Months)
Compound performance	53%		-1%

A lot happened this week.

Firstly me regular monthly purchase of iShares Physical Gold went through. I got 4 units at 2634.315p costing £106.87 after commission. That takes my holding up to 20 units and they are still flat, down by just £1.

Next I did what I usually do when OPTI:Optibiotix drops in price. I cheered myself up by buying some more. I had some cash in my AJ Bell account so I added £280 from my bank account as it's payday next week, and bought another 1,000 shares at 43.98p costing £449.75. That takes my total OPTI holding to 175,069. I should really stop now, but after six and a half years I'm still convinced in the story. The first generation products have got us to break even despite not being on the market for long, but the second generation products have staggering potential. I still see this as my retirement share.

I also had cash in my Hargreaves Lansdown SIPP and I've been beyond frustrated with the share price action of DDDD:4D Pharma, so I added £240 from my bank account and bought 1,254 shares at 35.0127p costing £451.01. I now have 15,139 of these but this purchase only dragged my SIPP average down from 130p to 107p, and my ISA average is 115p so they are down by 70%. I would buy loads more at this level, but I've been stung badly by pharma companies before so I daren't risk it, as the £17,000 I've spent on these already would wipe out half of my profits if they go bust.

This account fared much worse than the ISA as there was no star performer to mend the hole left by the OPTI:Optibiotix drop. Annual performance is woeful as I can't sell anything, and long term average slipped another 0.1%, with compound performance also dropping thanks to the increase in injection.

This is so deceptive as it looks almost flat for the last 12 months, but the cost line has been steadily rising as I bank profits and inject more cash.

There's the real picture. Woe and desperate misery.

The trading account looks like this after week 290 overall and week 30 of year 6.

			Weekly Change
Cash	£259.74		+£0
Portfolio cost	£2,374.14		+£0
Portfolio sell value (bid price - commission)	£788.04	(-66.8%)	+£22.86
Potential profits	£0.00		+£0
Year 6 Dividends	£0.00		+£0
Year 6 Profit	£0.00		+£0
Yr 6 projected avg monthly profit	£0.00	(0%)	+£0
Dividends	£60.10		+£0
Profit from sales	£937.88		+£0
Average monthly cash profit	£14.91	(7.5%)	-£0.05
(Sold stocks profit + Dividends - Fees / Months)

Remarkably this account has gone up two weeks in a row. Only by £22, but I'm not complaining. This week it was thanks to HUM:Hummingbird Resources and IQE:IQE, but in spite of DDDD:4D Pharma which dropped yet again.

Given the complete catastrophe this account has been, the long term performance of 7.5% is fairly remarkable, assuming I ever break even on my current holdings.

If this is the start of a recovery then it's going to take a long time at the current rate.

I need to get above the trend line next week to boost my morale.

It's pay day on Tuesday which means at the end of the week I will have enough money in my work pension to transfer some into my SIPP. I reckon I'll have about £2,400. I'm determined to stick to my plan and buy magic formula shares. One that qualifies for magic formula is CAML:Central Asia Metals, and I hate not being invested so will almost certainly get back in there. I sold them for 237p and the current price is 234p so they are virtually unchanged since then. The dividend ex-date is in April, so buying now will get me that too.

I've not completely refreshed my magic formula rankings as it would take forever, so I've re-ranked on P/E ratio because that's automatic, and updated the stats for a few of the top-ranked shares so see how they compare. I risk missing an amazing company that's emerged via recent results, but I can live with that until my next injection in June. The leader is ASHM:Ashmore Group, so assuming there are no changes between now and the transfer, those will be my other buy. Their stats have all improved since I last ran my calculations, and it appears they are taking advantage of a troubled market to invest in a few bargains in emerging markets. Their dividend ex-date is early March so I may just have time. If it looks like there will be a delay I may sell PAF:Pan African Resources as they have no dividend until December, buy ASHM:Ashmore Group now, and then buy back PAF when the cash comes through, as my review date for them isn't until November so I'll definitely want to have some for the next dividend.

Week 339 Review - First positive week of 2022

At last we have a positive week. No major fallers and a 2p increase in OPTI:Optibiotix helped hugely. The deficit between cost and value reduced by £3,777 to £55,851 and total portfolio value with cash went above the magic £100k at £100,108.

HUM:Hummingbird Resources and PAF:Pan African Resources both climbed 5% despite the price of gold bouncing above and below $1,800. 

JLP:Jubilee Metals also rose 5% but is still well down on where it should be.

IES:Invinity Energy climbed 6% after announcing a big new order.

Share of the Week is SBTX:SkinBioTherapeutics, which cast aside its recent dreadful form to climb 13% of my purchase price in the ISA and 15% in my SIPP.

Thank goodness we didn't dip below the injection line.

Bang on the trend line but really need to be well above it.

Here's the ISA and shares portfolio after week 27 of year 7.

			Weekly Change
Cash	£33.30		+£0
Portfolio cost	£72,195.21		+£0
Portfolio sell value (bid price-commission)	£46,566.98	(-35.5%)	+£1,934.66
Potential profits	£2,095.29		+£40
Yr 7 Dividends	£22.16		+£0
Yr 7 Profit from sales	£3,664.29		+£0
Yr 7 projected avg monthly profit	£588.64	(16.0%)	-£22.64
Total Dividends	£1,365.31		+£0
Total Profit from sales	£27,788.23		+£0
Average monthly cash profit	£368.82	(10.0%)	-£1.09
(Sold stocks profit + Dividends - Fees / Months)
Compound performance	65%		+0%

JLP:Jubilee Metals added £40 to potential profits. The fact it takes a 5% rise to do that shows how few shares I have left. Value up nicely and long term performance stays at 10% but I fear will slip below very soon.

As with the overall chart, just avoided dropping below the injection line

Still well below the trend line so no chance of recovery very soon.

The SIPP looks like this after week 323 overall and week 11 of year 7.

			Weekly Change
Cash	£571.47		+£159.84
Portfolio cost	£80,526.94		+£0
Portfolio sell value (bid price - commission)	£51,912.63	(-35.5%)	+£1,822.77
Potential profits	£124.25		+£56.98
Yr 7 Dividends	£81.54		+£0
Yr 7 Interest	£0		+£0
Yr 7 Profit from sales	£381.04		+£0
Yr 7 projected avg monthly profit	£168.97	(4.1%)	-£16.96
Total Dividends	£3,285.93		+£0
Total Interest	£0.20		+£0
Total Profit from sales	£24,105.67		+£0
Average monthly cash profit	£356.00	(8.6%)	-£1.11
(Sold stocks profit + Dividends - Fees / Months)
Compound performance	54%		+0%

Potential profits up £56 thanks to PAF:Pan African Resources, portfolio value up pleasingly and cash up due to a £30 tax rebate and my £130 monthly savings minus the AJ Bell SIPP admin charge of 16p.

Same story as the ISA

Slightly better as we're just above the trend line, but not enough to help flatten it.

The trading account looks like this after week 289 overall and week 29 of year 6.

			Weekly Change
Cash	£259.74		+£0
Portfolio cost	£2,374.14		+£0
Portfolio sell value (bid price - commission)	£765.18	(-67.8%)	+£20.41
Potential profits	£0.00		+£0
Year 6 Dividends	£0.00		+£0
Year 6 Profit	£0.00		+£0
Yr 6 projected avg monthly profit	£0.00	(0%)	+£0
Dividends	£60.10		+£0
Profit from sales	£937.88		+£0
Average monthly cash profit	£14.96	(7.6%)	-£0.06
(Sold stocks profit + Dividends - Fees / Months)

A positive week despite DDDD:4D Pharma slipping yet again, as HUM:Hummingbird Resources climbed 5%. Still looking pretty grim though, and didn't even make up half of last week's losses.

Looks flat rather than an up-tick

Still below the trend line. I feel like I've been writing that for a year - oh hold on - I have!

I'm beginning to wonder if the turn-around will ever come. I've been expecting good news on many fronts for months now, but it either doesn't arrive at all, or when it does is treated like bad news and the share price drops.

I seem to be invested in sectors that are just not popular at the moment. I bought magic formula shares because the price was already cheap, but all except one have dropped, and some have dropped significantly. At least they are all still paying good dividends, but they are not making up for the big drops in capital value.

I will be able to take another £2,000 from my work pension in a few weeks. I need to decide whether to put it into one of my ludicrously underpriced shares like OPTI:Optibiotix or DDDD:4D Pharma or stick to my guns and get some more magic formula shares. Despite my temptation to average down on OPTI and DDDD, I really should get the diversity into my SIPP that magic formula gives me.

Week 338 Review - It just keeps getting worse

Every week in 2022 has seen a fall in portfolio value. Despite OPTI:Optibiotix staying flat for the 2nd week in a row, there were big drops across the rest of the portfolio and the deficit between cost and value widened by £1,430 to an eye-watering £59,629 and overall portfolio value dropped to £96,171. The only relief is that it went much worse earlier in the week but rallied at the end. It's still a new record deficit though.

JLP:Jubilee Metals was the worst performer, slipping 23% of my original purchase price. I expected this to be at least 20p by now, but instead it's 14.7p.

POLY:Polymetal is getting hammered thanks to the Russians lurking on the Ukrainian border, but the gold price also slumped at the end of the week. These are down 10% which isn't supposed to happen to my magic formula shares.

BLU:Blue Star Capital is sliding rapidly after the recent spike. It fell another 15% this week to go 56% down.

CEY:Centamin fell 7% as the gold price slipped, and PAF:Pan African Resources dropped 6%, with the Blackrock World Gold Fund also falling 6% and HUM:Hummingbird Resources 5% as gold dropped. Frustratingly the gold price didn't drop that much, but it didn't stop all my miners being hit.

Share of the Week SMS:Smart Metering Systems hardly warrants the prize, rising just 2%, but if was further than the other four companies that ended the week higher than they started.

Injection line here we come - the mattress would have done the job after all

Well below the steep downward-facing trend line

Here's the ISA and shares portfolio after week 26 of year 7.

			Weekly Change
Cash	£33.30		+£0
Portfolio cost	£72,195.21		+£0
Portfolio sell value (bid price-commission)	£44,632.32	(-38.2%)	-£713.37
Potential profits	£2,055.29		-£200
Yr 7 Dividends	£22.16		+£0
Yr 7 Profit from sales	£3,664.29		+£0
Yr 7 projected avg monthly profit	£611.28	(16.6%)	-£24.45
Total Dividends	£1,365.31		+£0
Total Profit from sales	£27,788.23		+£0
Average monthly cash profit	£369.91	(10.0%)	-£1.10
(Sold stocks profit + Dividends - Fees / Months)
Compound performance	65%		+0%

Drop in potential profits thanks to JLP:Jubilee Metals, and relatively big drop in value considering OPTI:Optibiotix stayed flat. The 4% drop in DDDD:4D Pharma was a major contributor, and amazingly it came in a week that positive test results were announced for their asthma drug. So much for "this will bounce when we get good news".

Long term performance has dropped to 10% which is bang on target, but in a few weeks we'll slip below. Year 7 is still pretty good, and if I don't sell anything else in the next 6 months will give 8.3%, which given the state of my portfolio would be quite a good year.

As with the overall account, in severe danger of crossing the injection line.

A long way below the trend line
The SIPP looks like this after week 322 overall and week 10 of year 7.

			Weekly Change
Cash	£411.63		+£200.03
Portfolio cost	£80,526.94		+£0
Portfolio sell value (bid price - commission)	£50,089.86	(-37.8%)	-£661.00
Potential profits	£67.27		-£65.92
Yr 7 Dividends	£81.54		+£30.03
Yr 7 Interest	£0		+£0
Yr 7 Profit from sales	£381.04		+£0
Yr 7 projected avg monthly profit	£185.93	(4.5%)	-£6.20
Total Dividends	£3,285.93		+£30.03
Total Interest	£0.20		+£0
Total Profit from sales	£24,105.67		+£0
Average monthly cash profit	£357.11	(8.7%)	-£0.71
(Sold stocks profit + Dividends - Fees / Months)
Compound performance	54%		+0%

£170 tax rebate boosted cash, and £30 dividends came from CMCL:Caledonia Mining (£15), FXPO:Ferrexpo (£7) and SMS:Smart Metering Systems (£7). Potential profits were halved thanks to PAF:Pan African Resources and long term performance just dropped a little.

Same old story

A bit closer to the trend line but still below.

The trading account looks like this after week 288 overall and week 28 of year 6.

			Weekly Change
Cash	£259.74		+£0
Portfolio cost	£2,374.14		+£0
Portfolio sell value (bid price - commission)	£744.77	(-68.6%)	-£56.17
Potential profits	£0.00		+£0
Year 6 Dividends	£0.00		+£0
Year 6 Profit	£0.00		+£0
Yr 6 projected avg monthly profit	£0.00	(0%)	+£0
Dividends	£60.10		+£0
Profit from sales	£937.88		+£0
Average monthly cash profit	£15.02	(7.6%)	-£0.05
(Sold stocks profit + Dividends - Fees / Months)

What can I say? Yet another desperately bad week. Big drops and no hope.

I had to drop the Y access to £500 so we can watch the continued fall.

It was following the trend line down, but now it's dragging it steeper.

Not saying anything else. Every time there has been good news the share price has fallen further. There's nothing going to improve until we get out of this current malaise in stock markets.

Week 337 Review - Worse than the worst ever

If last week was the worst ever, then this week is even worse, albeit only £363 worse, which would normally be regarded as a flat week if it didn't result in the worst ever performance. The deficit between cost and value now stands at £58,198 and portfolio value is £97,401.

SBTX:SkinBioTherapeutics was the biggest loser, falling 8% in my ISA and 9% in my SIPP to go 34% down in just a few weeks since I bought them. My original plan was to try and buy back around 30p but I really didn't think they would fall that far.

FXPO:Ferrexpo fell 7% for the 2nd week in a row, no doubt fueled by the threat of a Russian invasion of Ukraine. They are now 46% down from when I bought them at what I thought was a bargain price. They've already yielded 5% dividend and more is due next Friday, so as long as they recover by May I'll have made an excellent return.

SMS:Smart Metering Systems has been dropping ever since the 800p placing. They fell 6% this week to 735p so those taking part in the placing are probably a bit miffed. My holding is 23% down and my dividend so far is only 0.7% but there will be another payout next week to give this a little boost.

BLU:Blue Star Capital was well and truly pumped recently but is now dropping like a stone. It went down 5% this week to go 41% down altogether. SatoshiPay had better work out as I want to be rid of them.

IES:Invinity Energy has been dropping steadily as it becomes clear nobody wants their batteries. They fell 5% this week and are 83% down.

There were a few glimmers of hope amongst my gold miners, with CEY:Centaminclimbing 5%, but Share of the Week goes toPAF:Pan African Resources which climbed 7% and at 13% up is one of my very few profitable shares.

Not quite below the injection line - yet.

Still well below the trend line and next week the last memory of being in the black will disappear off the chart.

Here's the ISA and shares portfolio after week 25 of year 7.

			Weekly Change
Cash	£33.30		+£0
Portfolio cost	£72,195.21		+£0
Portfolio sell value (bid price-commission)	£45,345.69	(-37.2%)	-£153.22
Potential profits	£2,255.29		-£20
Yr 7 Dividends	£22.16		+£0
Yr 7 Profit from sales	£3,664.29		+£0
Yr 7 projected avg monthly profit	£635.73	(17.3%)	-£27.49
Total Dividends	£1,365.31		+£0
Total Profit from sales	£27,788.23		+£0
Average monthly cash profit	£371.01	(10.1%)	-£1.10
(Sold stocks profit + Dividends - Fees / Months)
Compound performance	65%		+0%

Hardly any change. Even the drop in JLP:Jubilee Metals was only enough to drop potential profits by £20.

So, so rubbish

Well below the trend line

The SIPP looks like this after week 321 overall and week 9 of year 7.

			Weekly Change
Cash	£211.60		+£0
Portfolio cost	£80,526.94		+£0
Portfolio sell value (bid price - commission)	£50,750.86	(-37.0%)	-£192.33
Potential profits	£133.19		+£69.56
Yr 7 Dividends	£51.51		+£0
Yr 7 Interest	£0		+£0
Yr 7 Profit from sales	£381.04		+£0
Yr 7 projected avg monthly profit	£192.13	(4.7%)	-£24.02
Total Dividends	£3,255.90		+£0
Total Interest	£0.20		+£0
Total Profit from sales	£24,105.67		+£0
Average monthly cash profit	£357.82	(8.7%)	-£1.12
(Sold stocks profit + Dividends - Fees / Months)
Compound performance	54%		+0%

Hardly any change. The 7% rise in share price for PAF:Pan Aftrican Resources boosted potential profits by £69 so not all bad news.

Same as ISA

Also well below trend line.

The trading account looks like this after week 287 overall and week 27 of year 6.

			Weekly Change
Cash	£259.74		+£0
Portfolio cost	£2,374.14		+£0
Portfolio sell value (bid price - commission)	£800.94	(-66.3%)	-£17.73
Potential profits	£0.00		+£0
Year 6 Dividends	£0.00		+£0
Year 6 Profit	£0.00		+£0
Yr 6 projected avg monthly profit	£0.00	(0%)	+£0
Dividends	£60.10		+£0
Profit from sales	£937.88		+£0
Average monthly cash profit	£15.07	(7.6%)	-£0.05
(Sold stocks profit + Dividends - Fees / Months)

The relentless drop continues. The portfolio is now two thirds down on purchase price, and that was over a year ago. Some great trading performance that is!

Utterly horrible

Not only following the trend line but below it.

I'm late writing up again, as my heart isn't in it. At the time of writing my portfolio has lost another £8,000 and 2022 is a catastrophe. I can't see it turning around before Friday so no doubt I'll be late writing this weeks up too.

Week 336 Review - Miserable start to 2022

A desperately bad week, with most of my big holdings taking big drops and the deficit between cost and value widening by £6,249 to £57,835 and portfolio value dropping below £100k to £97,764.

FXPO:Ferrexpo dropped 7%, probably due to the uncertain situation on the Ukraine border, despite FXPO being nowhere near that. It also went ex-dividend so at least there's some cash coming soon.

SBTX:SkinBioTherapeutics also dropped 7% as one of my worst timed purchases continues a downward spiral. News on sales or partner product development can't come soon enough, but all we have is silence.

BLU:Blue Star Capital was bound to ease off as people take profits following the recent rise. They dropped 5% of my original purchase price.

Biggest hit to value was OPTI:Optibiotix falling 5% which is 3p and contributed £5,100 of this week's drop. We're overdue so much news and it really needs to come soon.

Share of the Week was the only one to climb 5% or more as JLP:Jubilee Metals went up by 7% and seems to be slowly creeping up to where it should be.

Closest to the injection line for over a year.

Worst ever performance, just as I thought it couldn't get any worse.

Here's the ISA and shares portfolio after week 24 of year 7.

			Weekly Change
Cash	£33.30		+£0
Portfolio cost	£72,195.21		+£0
Portfolio sell value (bid price-commission)	£45,498.91	(-37.0%)	-£3,105.00
Potential profits	£2,275.29		+£60
Yr 7 Dividends	£22.16		+£0
Yr 7 Profit from sales	£3,664.29		+£0
Yr 7 projected avg monthly profit	£663.22	(18.0%)	-£27.80
Total Dividends	£1,365.31		+£0
Total Profit from sales	£27,788.23		+£0
Average monthly cash profit	£372.11	(10.1%)	-£1.12
(Sold stocks profit + Dividends - Fees / Months)
Compound performance	65%		+0%

Massive drop in value but £60 increase in potential profits thanks to JLP:Jubilee Metals. Long term performance still above target.

As with the overall portfolio the closest to injection line for over a year.

Utterly desperate.

The SIPP looks like this after week 320 overall and week 8 of year 7.

			Weekly Change
Cash	£211.60		-£104.52
Portfolio cost	£80,526.94		+£104.52
Portfolio sell value (bid price - commission)	£50,943.19	(-36.7%)	-£3,086.92
Potential profits	£63.63		+£38.80
Yr 7 Dividends	£51.51		+£0
Yr 7 Interest	£0		+£0
Yr 7 Profit from sales	£381.04		+£0
Yr 7 projected avg monthly profit	£216.15	(5.3%)	-£30.88
Total Dividends	£3,255.90		+£0
Total Interest	£0.20		+£0
Total Profit from sales	£24,105.67		+£0
Average monthly cash profit	£358.94	(8.7%)	-£1.12
(Sold stocks profit + Dividends - Fees / Months)
Compound performance	54%		+0%

Automatic investment in iShares Physical Gold fund reduced cash by £104 and increased portfolio cost. Massive drop in value but potential profits up £38 thanks to PAF:Pan African Resources. Long term performance needs a boost to get to target but there's no chance of that any time soon.

A familiar story

As with everything else, the worst performance ever.

The trading account looks like this after week 286 overall and week 26 of year 6.

			Weekly Change
Cash	£259.74		+£0
Portfolio cost	£2,374.14		+£0
Portfolio sell value (bid price - commission)	£818.67	(-65.5%)	-£57.35
Potential profits	£0.00		+£0
Year 6 Dividends	£0.00		+£0
Year 6 Profit	£0.00		+£0
Yr 6 projected avg monthly profit	£0.00	(0%)	+£0
Dividends	£60.10		+£0
Profit from sales	£937.88		+£0
Average monthly cash profit	£15.12	(7.6%)	-£0.05
(Sold stocks profit + Dividends - Fees / Months)

It goes without saying this is as bad as everything else, in fact significantly worse.

Urrrg.

Continues the relentless decline.

Late writing up this week as I'm so miserable. At the halfway point of this week the portfolio is down another £700 so it is still getting worse. All I can do is hang on and hope for some sort of recovery, but at the moment I can't see any rays of hope. Every time there's a tick upwards it's followed by a bigger drop. Good news is met by at best stagnation but more often with a drop in price. Nothing to do but steel oneself for the next disappointing update.

Week 335 Review - Declines across much of the portfolio

Not a great start to 2022, with some big falls across the portfolio resulting in a drop of £1,282 despite OPTI:Optibiotix staying flat. That extends the deficit between cost and value to £51,586 and reduces total value to £104,014.

The biggest faller was JLP:Jubilee Metals, although that does tend to happen almost every week due to my low purchase price. This week it dropped 11% but is still 254% up.

Next biggest faller is one of my most disappointing recent purchases POLY:Polymetal. It dropped 6% in the SIPP and 8% in the ISA mainly due to political concerns in Ukraine. However, FXPO:Ferrexpo is also in Ukraine and was up this week, so I think it's more that gold miners are just plain out of favour.

TLOU:Tlou Energy is still dropping a worrying amount, this week falling 7% for no clear reason. I'm happy with this as a long term investment, but it's too high risk for me to invest any more, even though it's temptingly cheap right now.

DDDD:4D Pharma continues to be an utter disaster, dropping another 6% this week to go 60% down on my purchase price. Even if it doubles from here I'll still be making a loss. I'm over £10,000 down now, having invested £16,641 making this my second biggest holding by a long way. I can't believe I was daft enough to believe listing on Nasdaq would cause a re-rate upwards, then it's more than halved in value since then.

It's not all doom and gloom this week. It seems the volatile market is helping PLUS:Plus500, which rose by 5% this week and is now only 11% down. Dividends are still rolling in and I don't need to review my holding until the end of May so plenty of time to get back into profit.

Share of the Week is BLU:Blue Star Capital which climbed another 14% as its recovery continues. I am now only 31% down, which compared to the rest of the portfolio isn't bad. Shame I only invested £500. I still think they are a bit rubbish so won't be putting any more in.

Almost flat.

Following the trend line downwards instead of trying to pull it flat.

Here's the ISA and shares portfolio after week 23 of year 7.

			Weekly Change
Cash	£33.30		-£3.75
Portfolio cost	£72,195.21		+£0
Portfolio sell value (bid price-commission)	£48,603.91	(-32.7%)	-£594.04
Potential profits	£2,215.29		-£100
Yr 7 Dividends	£22.16		+£0
Yr 7 Profit from sales	£3,664.29		+£0
Yr 7 projected avg monthly profit	£691.02	(18.8%)	-£32.14
Total Dividends	£1,365.31		+£0
Total Profit from sales	£27,788.23		+£0
Average monthly cash profit	£373.23	(10.1%)	-£1.16
(Sold stocks profit + Dividends - Fees / Months)
Compound performance	65%		+0%

JLP:Jubilee Metals dropped by £100 to dent potential profits, and the rest of the portfolio lost £494. The ISA monthly charge reduced cash.

I so need this to start going up.

Still below the trend line and dragging it steeper.

The SIPP looks like this after week 319 overall and week 7 of year 7.

			Weekly Change
Cash	£316.12		+£86.38
Portfolio cost	£80,422.42		+£0
Portfolio sell value (bid price - commission)	£53,925.59	(-32.9%)	-£640.61
Potential profits	£24.83		-£22.77
Yr 7 Dividends	£51.51		+£0
Yr 7 Interest	£0		+£0
Yr 7 Profit from sales	£381.04		+£0
Yr 7 projected avg monthly profit	£247.03	(6.0%)	-£53.22
Total Dividends	£3,255.90		+£0
Total Interest	£0.20		+£0
Total Profit from sales	£24,105.67		+£0
Average monthly cash profit	£360.06	(8.8%)	-£1.36
(Sold stocks profit + Dividends - Fees / Months)
Compound performance	54%		+0%

Cash went up after a £120 injection to my AJ Bell SIPP which hasn't been invested yet, but the monthly charges were also taken out and I did a bit of a re-set as my adding and subtracting payments must have missed a few lately and it had got out of sync. PAF:Pan African Resources is my only share in profit and that fell this week, so potential profits are a miserable £22. Long term performance is below target so I need my Magic Formula shares to wake up.

Pretty much the same as the ISA.

At least this one is fractionally above the trend line. I doubt this is flattening it much though.

The trading account looks like this after week 285 overall and week 25 of year 6.

			Weekly Change
Cash	£259.74		+£0
Portfolio cost	£2,374.14		+£0
Portfolio sell value (bid price - commission)	£876.02	(-63.1%)	-£47.91
Potential profits	£0.00		+£0
Year 6 Dividends	£0.00		+£0
Year 6 Profit	£0.00		+£0
Yr 6 projected avg monthly profit	£0.00	(0%)	+£0
Dividends	£60.10		+£0
Profit from sales	£937.88		+£0
Average monthly cash profit	£15.17	(7.7%)	-£0.06
(Sold stocks profit + Dividends - Fees / Months)

Good grief. Can this get any worse? Yet another big drop in value largely thanks to DDDD:4D Pharma. I haven't sold anything for a year - what sort of trading account does that? I'm utterly rubbish at it.

Move along please, nothing to see here.

I'm really impressed with how neatly we're following the trend line downwards.

We were expecting news from DDDD:4D Pharma, OPTI:Optibiotix and SBTX:SkinBioTherapeutics before Christmas, but it never appeared. Let's hope it comes soon in 2022 as these shares have the ability to turn around my current desperate performance very quickly, but only when the news hits.